Antidepressant Formulations in India: A Review of Dosage Forms and Manufacturers

Depression is a common and serious mental health disorder that affects how individuals feel, think, and behave¹. It is characterized by persistent sadness, loss of interest in daily activities, and a reduced ability to function effectively over time². Unlike temporary emotional fluctuations, depressive symptoms tend to persist and can significantly interfere with personal, social, and occupational aspects of life¹.

The development of depression is multifactorial, involving a combination of genetic, biological, environmental, and psychological influences²^,?. Factors such as chronic stress, traumatic experiences, and major life changes increase the likelihood of developing the disorder. Epidemiological studies have also shown that depression is more prevalent among women compared to men¹,³. If left untreated, it can lead to serious consequences, including impaired quality of life and an increased risk of suicide⁴. These impacts highlight the importance of early diagnosis and effective management strategies.

From a neurobiological perspective, depression is associated with alterations in key neurotransmitters, including serotonin, norepinephrine, and dopamine⁵. The monoamine hypothesis suggests that a deficiency in these neurotransmitters plays a central role in the pathophysiology of depression^6,7. In addition to neurotransmitter imbalance, recent research has emphasized the role of impaired neuroplasticity, inflammatory processes, and dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis in the progression of the disorder⁸

Clinically, depression presents with a range of symptoms such as low mood, fatigue, sleep disturbances, changes in appetite, poor concentration, and feelings of hopelessness¹. Based on the severity and duration of symptoms, depression may be classified as mild, moderate, or severe?.

Antidepressant drugs are categorized into several classes based on their mechanism of action, including selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and atypical antidepressants⁹. Among these, SSRIs are most commonly prescribed due to their safety and tolerability profile.

Symptoms

During a depressive episode, an individual may experience a persistent low mood, often described as sadness, irritability, or a feeling of emptiness. There is usually a noticeable loss of interest or pleasure in activities that were once enjoyable¹.

Unlike normal mood variations, a depressive episode is more intense and prolonged. These symptoms are present for most of the day, nearly every day, and typically last for at least two weeks¹. In addition, several other symptoms may be observed, including poor concentration, excessive guilt or feelings of low self-worth, and a sense of hopelessness about the future. Some individuals may also experience thoughts related to death or suicide². Physical and behavioral changes are also common, such as disturbed sleep, changes in appetite or weight, and persistent fatigue or low energy levels¹.

Depression can significantly interfere with a person’s ability to function effectively in daily life, including at home, in social interactions, at work, and in academic settings¹.

Based on the number and severity of symptoms, as well as their impact on daily functioning, depressive episodes are generally classified as mild, moderate, or severe¹.

Types of depression

A single episode depressive disorder refers to the occurrence of only one depressive episode. In contrast, recurrent depressive disorder involves two or more episodes over time¹. In bipolar disorder, depressive episodes alternate with periods of mania. These manic phases may include elevated or irritable mood, increased activity or energy, excessive talkativeness, rapid thoughts, increased self-esteem, reduced need for sleep, distractibility, and impulsive or risky behavior⁸.

Diagnosis and Treatment

Depression is a manageable mental health condition, and several effective treatment approaches are available. The choice of therapy depends on the severity of symptoms and the individual’s clinical condition. For mild depression, psychological interventions such as counseling or cognitive behavioral therapy are usually recommended as the first line of treatment ^[1]. In moderate to severe cases, a combination of psychotherapy and antidepressant medication is often required for better outcomes ^[1,4]. Pharmacological treatment is generally not necessary in mild cases unless symptoms persist.

The pharmacological management of depression mainly involves the use of antidepressant medications. These drugs are classified based on their mechanism of action, particularly their effects on neurotransmitters like serotonin, norepinephrine, and dopamine ^[9]. Each class differs in terms of therapeutic effects, safety, and tolerability.

Antidepressants: Classification

Antidepressants are grouped according to how they influence neurotransmitter systems in the brain.

1. Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs act by selectively inhibiting the reuptake of serotonin (5-HT), thereby increasing its availability in the synaptic cleft and improving mood. They are widely used due to their better safety and tolerability profile ^[10,11].

Examples:
Fluoxetine, Sertraline, Escitalopram, Paroxetine, Citalopram

2. Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs inhibit the reuptake of both serotonin and norepinephrine, enhancing their levels and improving mood regulation ^[10,12].

Examples:
Venlafaxine, Desvenlafaxine, Duloxetine

3. Tricyclic Antidepressants (TCAs)

TCAs block the reuptake of norepinephrine and serotonin but are associated with a higher incidence of side effects due to their non-selective receptor interactions ^[12,13].

Examples:
Amitriptyline, Imipramine, Clomipramine, Nortriptyline

4. Monoamine Oxidase Inhibitors (MAOIs)

MAOIs inhibit the enzyme monoamine oxidase, preventing the breakdown of monoamine neurotransmitters. Their use is limited due to potential dietary restrictions and drug interactions ^[10,12].

Examples:
Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline

5. Atypical Antidepressants

This group includes drugs with unique or mixed mechanisms of action that do not fit into conventional classes. They are often considered when first-line treatments are not effective ^[10,13]. Examples:

• Bupropion (dopamine–norepinephrine reuptake inhibitor)
• Mirtazapine (noradrenergic and specific serotonergic antidepressant)
• Trazodone (serotonin antagonist and reuptake inhibitor)
• Vortioxetine (serotonin modulator)

6. Other/Newer Antidepressants

Recent developments have introduced drugs targeting multiple receptors and pathways, especially for treatment-resistant depression ^[11].

Examples:
Vilazodone, Agomelatine, Esketamine (nasal formulation)

ANTIDEPRESSANTS: CLASSIFICATION AND MARKETED FORMULATIONS

Selective Serotonin Reuptake Inhibitors (SSRIs)

Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly prescribed antidepressants due to their favorable safety and tolerability profile. Drugs such as escitalopram, sertraline, and fluoxetine act by selectively inhibiting the reuptake of serotonin (5-HT) into the presynaptic neuron, thereby increasing its availability in the synaptic cleft ^[14]. This enhancement of serotonergic transmission contributes to mood stabilization and overall improvement in depressive symptoms.

Compared to older antidepressants, SSRIs produce minimal anticholinergic and sedative effects, making them the preferred first-line treatment in most clinical cases.

Table 1: Marketed SSRIs Antidepressants (India)

Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)

Serotonin–norepinephrine reuptake inhibitors (SNRIs), such as duloxetine and venlafaxine, act by inhibiting the reuptake of both serotonin and norepinephrine. This dual mechanism enhances neurotransmitter availability and may provide improved therapeutic outcomes, particularly in patients who show an inadequate response to SSRIs ^[14].

Additionally, SNRIs are beneficial in managing comorbid conditions such as neuropathic pain and anxiety disorders.

Table 2: Marketed SNRIs Antidepressants (India)

Tricyclic Antidepressants (TCAs)

Tricyclic antidepressants (TCAs), including amitriptyline and dothiepin, are among the earliest classes of antidepressant drugs. They exert their effect by inhibiting the reuptake of norepinephrine and serotonin. However, due to their non-selective interaction with histaminergic, cholinergic, and adrenergic receptors, they are associated with a higher incidence of adverse effects such as sedation, dry mouth, and cardiovascular complications ^[11,12].

As a result, their clinical use has declined, although they remain useful in selected or treatment-resistant cases.

Table 3: Marketed TCAs Antidepressants (India)

Monoamine Oxidase Inhibitors (MAOIs)

Monoamine oxidase inhibitors (MAOIs) act by inhibiting the enzyme monoamine oxidase, which is responsible for the breakdown of neurotransmitters such as serotonin, norepinephrine, and dopamine. This results in increased neurotransmitter levels in the brain ^[15].

However, their use is limited due to significant dietary restrictions and the potential for serious drug interactions.

Table 4: Marketed MAOIs (India*)

*Availability may vary in the Indian pharmaceutical market.

Atypical Antidepressants

Atypical antidepressants include a diverse group of drugs with distinct mechanisms of action. For example, bupropion inhibits the reuptake of dopamine and norepinephrine, whereas mirtazapine enhances noradrenergic and serotonergic neurotransmission through receptor modulation ^[16].

These agents are often used in patients who do not respond adequately to first-line therapies or who experience intolerable side effects.

Table 5: Marketed Atypical Antidepressants (India)

Extended-Release Antidepressants: Overview

Antidepressants such as SSRIs, SNRIs, and atypical agents like bupropion are widely used in clinical practice ^[11]. However, conventional immediate-release formulations often result in fluctuations in plasma drug concentrations, which may reduce therapeutic effectiveness and increase the likelihood of adverse effects, particularly at peak levels ^[5].

Extended-release (ER) formulations are designed to overcome these limitations by providing controlled drug release over an extended period ^[19]. These systems help maintain relatively stable plasma drug concentrations, reduce dosing frequency, and improve patient adherence—an important factor in chronic conditions such as depression ^[18].

By minimizing peak–trough fluctuations, ER formulations can also reduce dose-dependent side effects, including insomnia, anxiety, and seizure risk associated with certain antidepressants ^[19].

Various formulation strategies are used in ER systems, including hydrophilic matrix systems (e.g., hydroxypropyl methylcellulose), hydrophobic matrices, coated reservoir systems, and osmotic drug delivery systems. These approaches regulate drug release through mechanisms such as diffusion, erosion, and osmotic pressure, enabling controlled or near zero-order release kinetics ^[20].

Even drugs with relatively long half-lives, such as bupropion and venlafaxine, are commonly formulated as extended-release products. This is because the rate of drug absorption plays a crucial role in determining plasma concentration profiles. By controlling drug release, ER formulations improve tolerability and therapeutic outcomes ^[21].

Overall, extended-release antidepressant formulations represent a significant advancement in pharmaceutical technology, aligning drug delivery with pharmacokinetic and pharmacodynamic requirements to optimize clinical outcomes ^[22].

Table 6: Marketed Extended-Release Antidepressant Dosage Forms (India)